InChI key
IPEHBUMCGVEMRF-UHFFFAOYSA-N
SMILES string
NC(=O)c1cnccn1
InChI
1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)
grade
pharmaceutical primary standard
API family
pyrazinamide
manufacturer/tradename
EDQM
mp
189-191 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Pyrazinamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
P R Donald et al.
Tuberculosis (Edinburgh, Scotland), 92(1), 1-8 (2011-07-29)
Pyrazinamide (PZA) is an essential sterilizing drug and with rifampicin enables six-month short-course antituberculosis chemotherapy. Despite routine use for nearly forty years uncertainty remains regarding the most appropriate PZA dosage for children. In view of this uncertainty literature relating to
Kwok Chiu Chang et al.
Antimicrobial agents and chemotherapy, 55(10), 4499-4505 (2011-07-20)
Standard culture-based testing of the susceptibility of Mycobacterium tuberculosis to pyrazinamide is difficult to perform. This systematic review with meta-analyses evaluated the roles of molecular assays targeting pncA and of pyrazinamidase assays. PubMed and Embase were searched for relevant publications
E Cambau et al.
The Journal of antimicrobial chemotherapy, 70(3), 686-696 (2015-01-15)
Treatment outcome of MDR-TB is critically dependent on the proper use of second-line drugs as per the result of in vitro drug susceptibility testing (DST). We aimed to establish a standardized DST procedure based on quantitative determination of drug resistance
A Somoskovi et al.
Respiratory research, 2(3), 164-168 (2001-11-01)
Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an
Tawanda Gumbo et al.
The Journal of antimicrobial chemotherapy, 69(9), 2420-2425 (2014-05-14)
To identify the pyrazinamide MIC above which standard combination therapy fails. MICs of pyrazinamide were determined for Mycobacterium tuberculosis isolates, cultured from 58 patients in a previous randomized clinical trial in Cape Town, South Africa. The MICs were determined using
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持